Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Comment on prognostic and therapeutic implications of mTORC2 and rictor expression in human breast cancer.

Wazir U, Newbold RF, Jiang WG, Sharma AK, Mokbel K.

Breast Cancer Res Treat. 2012 Dec;136(3):927; author reply 928-9. doi: 10.1007/s10549-012-2248-5. Epub 2012 Sep 29. No abstract available.

PMID:
23053643
2.

Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

Li H, Lin J, Wang X, Yao G, Wang L, Zheng H, Yang C, Jia C, Liu A, Bai X.

Breast Cancer Res Treat. 2012 Aug;134(3):1057-66. doi: 10.1007/s10549-012-2036-2. Epub 2012 Apr 4.

PMID:
22476852
3.

mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.

Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X, Zhang N.

Cancer Res. 2010 Nov 15;70(22):9360-70. doi: 10.1158/0008-5472.CAN-10-0207. Epub 2010 Oct 26.

4.

Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.

Seidel J, Kunc K, Possinger K, Jehn C, Lüftner D.

Biochem Biophys Res Commun. 2011 Oct 14;414(1):226-32. doi: 10.1016/j.bbrc.2011.09.062. Epub 2011 Sep 17.

PMID:
21945930
5.

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.

Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J.

Cancer Res. 2007 Dec 15;67(24):11712-20.

6.

BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation.

Anderson LR, Sutherland RL, Butt AJ.

Oncogene. 2010 Jan 28;29(4):527-38. doi: 10.1038/onc.2009.362. Epub 2009 Nov 2.

PMID:
19881545
7.

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ.

Cancer Res. 2010 Nov 15;70(22):9391-401. doi: 10.1158/0008-5472.CAN-10-0911. Epub 2010 Sep 21.

8.

Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.

Rocha A, Azevedo I, Soares R.

J Cell Biochem. 2008 Feb 1;103(2):607-14.

PMID:
17614352
9.

Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration.

Liao SJ, Zhou YH, Yuan Y, Li D, Wu FH, Wang Q, Zhu JH, Yan B, Wei JJ, Zhang GM, Feng ZH.

Breast Cancer Res Treat. 2012 Jun;133(3):853-63. doi: 10.1007/s10549-011-1844-0. Epub 2011 Nov 1.

PMID:
22042369
10.

PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.

Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.

PMID:
21181437
11.

Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.

Kim EK, Yun SJ, Ha JM, Kim YW, Jin IH, Yun J, Shin HK, Song SH, Kim JH, Lee JS, Kim CD, Bae SS.

Oncogene. 2011 Jun 30;30(26):2954-63. doi: 10.1038/onc.2011.22. Epub 2011 Feb 21.

PMID:
21339740
12.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

13.

Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells.

Zhang YG, Du Q, Fang WG, Jin ML, Tian XX.

Int J Oncol. 2008 Sep;33(3):595-602.

PMID:
18695891
14.

Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.

Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, Karlan B, Mehta R, Koeffler HP.

Oncogene. 2010 Jan 14;29(2):285-96. doi: 10.1038/onc.2009.335. Epub 2009 Oct 26.

PMID:
19855437
15.

Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.

Zhi X, Wang Y, Yu J, Yu J, Zhang L, Yin L, Zhou P.

IUBMB Life. 2012 Nov;64(11):911-20. doi: 10.1002/iub.1086.

17.

Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.

Behera R, Kumar V, Lohite K, Karnik S, Kundu GC.

Carcinogenesis. 2010 Feb;31(2):192-200. doi: 10.1093/carcin/bgp289. Epub 2009 Nov 19.

PMID:
19926637
18.

Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines.

Fallahian F, Karami-Tehrani F, Salami S, Aghaei M.

FEBS J. 2011 Sep;278(18):3360-9. doi: 10.1111/j.1742-4658.2011.08260.x. Epub 2011 Aug 16.

19.

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ.

Br J Cancer. 2009 Nov 17;101(10):1699-708. doi: 10.1038/sj.bjc.6605381. Epub 2009 Oct 27.

20.

Cross-talk between Notch and EGFR signaling in human breast cancer cells.

Dai J, Ma D, Zang S, Guo D, Qu X, Ye J, Ji C.

Cancer Invest. 2009 Jun;27(5):533-40. doi: 10.1080/07357900802563036.

PMID:
19219656

Supplemental Content

Support Center